What Campral (Acamprosate) Is and What It Treats

Campral is the brand name for acamprosate calcium, a prescription medication approved by the FDA for maintaining abstinence in alcohol use disorder. It is taken by mouth as a tablet and is used after a patient has stopped drinking to reduce the risk of relapse.

Acamprosate works on the glutamate and GABA systems, the two neurotransmitter systems most disrupted by heavy alcohol use. Alcohol suppresses glutamate signaling during active drinking, and when the alcohol is removed, the glutamate system rebounds into an overactive state that drives withdrawal symptoms.

Campral is not classified as a benzodiazepine and does not bind to benzodiazepine receptors. It is not a sedative, not a controlled substance, and does not cause dependence or withdrawal symptoms of its own.

The medication is typically prescribed at 666 mg three times daily, for a total daily dose of roughly 2 grams. It must be taken consistently, even during periods when the patient feels no cravings, for its effects to build up.

Because acamprosate acts on the glutamate system, which is also hyperactive in benzodiazepine withdrawal, some physicians and patients have wondered whether Campral might help with benzo detox symptoms.

The Theoretical Case for Campral in Benzodiazepine Withdrawal

Acute alcohol withdrawal and benzodiazepine withdrawal share a common underlying mechanism: glutamate rebound after prolonged GABA enhancement. Both alcohol and benzodiazepines enhance GABA activity during use, and both produce withdrawal symptoms driven by runaway glutamate signaling when removed.

This pharmacological overlap is why benzodiazepines themselves are used to treat severe alcohol withdrawal. They replace the GABA enhancement that alcohol was providing.

The same logic has led some clinicians to ask whether a medication that calms glutamate might also ease benzodiazepine withdrawal symptoms. In theory, Campral could reduce glutamate-driven symptoms like anxiety, insomnia, akathisia, and sensory sensitivity during a benzo taper.

These symptoms are among the most distressing experiences in protracted benzodiazepine withdrawal and are not always well controlled by slower tapering alone. Patients in benzodiazepine tapering communities have occasionally reported trying Campral with their doctors’ approval, with mixed results.

The evidence base is essentially limited to anecdotal reports and indirect pharmacological reasoning. There are no controlled trials of Campral for benzodiazepine withdrawal at the time of this writing.

Why Most Physicians Hesitate to Prescribe Campral for Benzo Detox

Off-label prescribing requires a physician to weigh the theoretical benefit against the lack of evidence for an unapproved use. Most prescribers are uncomfortable making that trade-off without published studies or clinical guidelines to support the decision.

Many physicians are also unfamiliar with the pharmacology of protracted benzodiazepine withdrawal and the specific symptoms patients experience during long tapers. Without this background, the theoretical case for Campral is harder to appreciate.

There is also the practical concern that adding another medication during a benzodiazepine taper can complicate the picture. If symptoms improve, the patient cannot be sure whether Campral helped or whether the taper stabilized on its own.

If symptoms worsen, it becomes difficult to tell whether the added medication caused the worsening or whether the taper itself was the problem. This is why experienced tapering physicians tend to minimize medication changes during active dose reductions.

For patients interested in trying Campral for benzodiazepine withdrawal, the conversation needs to happen with a physician who understands both the medication and the taper process. Without that specialized knowledge, a Campral trial is more likely to add confusion than clarity.

Typical Campral Dosing When Used Off-Label

When Campral is used for its approved indication in alcohol use disorder, the standard dose is 666 mg three times daily with meals. This schedule is chosen to maintain steady blood levels throughout the day given the medication’s pharmacokinetics.

Physicians who have tried Campral for benzodiazepine withdrawal symptoms have generally used the same dosing pattern. There is no established alternative dosing for off-label use in benzo tapering.

Some patients are started at a lower dose and titrated up to minimize the main side effect, which is diarrhea. Acamprosate can cause gastrointestinal upset in a meaningful minority of patients, which can itself be uncomfortable during an already-challenging taper.

The medication typically takes several days to reach steady state in the bloodstream. Any assessment of whether Campral is helping should account for this ramp-up period rather than expecting immediate effects.

Like all trials of off-label medications during benzodiazepine tapering, a Campral trial should be time-limited with clear criteria for continuing or stopping. Open-ended trials make it harder to know whether the medication is doing anything useful.

Other Medications That Have Been Tried for Benzodiazepine Withdrawal

Several other medications have been discussed in benzodiazepine tapering literature and patient communities as potential adjuncts during tapering. None have strong evidence, and none replace gradual dose reduction as the central treatment.

Pregabalin (Lyrica) and gabapentin (Neurontin) act on calcium channels and have been used off-label to help with benzo withdrawal anxiety. Both carry their own risk of dependence, which is a significant drawback in patients already tapering off a dependence-forming medication.

Pentoxifylline, a medication used primarily for peripheral vascular disease, has been discussed based on its effects on cytokines and neuroinflammation. The evidence for any benefit in benzo withdrawal is limited to small reports and theoretical reasoning.

Beta blockers like propranolol are sometimes used to manage the physical symptoms of withdrawal, including rapid heart rate and tremors. They do not address the underlying neurological destabilization but can make day-to-day functioning more tolerable.

None of these adjunct medications are a substitute for a properly paced taper. Dr. Leeds generally avoids stacking additional psychoactive medications during benzodiazepine withdrawal unless the individual patient’s situation calls for it.

What Works More Reliably Than Campral for Benzodiazepine Tapering

The most reliable way to manage benzodiazepine withdrawal symptoms is to slow the taper until the nervous system can tolerate each reduction. A schedule that is too fast generates symptoms that no adjunct medication can fully offset.

Hyperbolic tapering, in which dose reductions become progressively smaller as the total dose decreases, is supported by both the Ashton Manual and the Maudsley Deprescribing Guidelines. This approach aligns the taper rate with the underlying pharmacology of GABA-A receptor occupancy.

Compound pharmacy liquid formulations make precise dose adjustments possible at lower levels, where standard tablets cannot deliver fractions of a milligram. These formulations enable the small, frequent reductions that many patients tolerate better than larger steps.

Holding the current dose when symptoms flare is a protective strategy, not a sign of failure. A hold allows the nervous system to stabilize before the next reduction, and in many cases shortens the overall taper by preventing a destabilizing cycle of pushed-too-hard reductions.

Sleep support, nervous system regulation practices, and patient education about BIND all contribute to tolerability during the taper. These interventions tend to produce more reliable results than adding speculative medications.

Discussing Medication Options With a Benzodiazepine Specialist

Questions about off-label medications like Campral, pentoxifylline, or gabapentinoids for benzodiazepine withdrawal are best brought to a physician who specializes in benzodiazepine tapering. A specialist can evaluate the evidence, the patient’s situation, and the risks of adding another medication during active withdrawal.

Dr. Leeds provides individualized benzodiazepine tapering using the Ashton Manual crossover protocol, hyperbolic dose reduction, and compound pharmacy formulations. Patients work directly with Dr. Leeds throughout the taper, with weekly telemedicine appointments that allow for close monitoring and real-time adjustments.

The practice focuses on benzodiazepine deprescribing and psychiatric medication tapering, not addiction-focused detox. This distinction matters for patients whose withdrawal is a consequence of prescribed benzodiazepine use rather than recreational misuse.

Patients interested in discussing Campral or other adjunct medications alongside a benzodiazepine taper can schedule an initial consultation through the contact form on this website. An initial consultation does not establish a physician-patient relationship and is useful for exploring whether a customized taper plan is the right fit.

Medically supervised tapering remains the most reliable path through benzodiazepine withdrawal. Adjunct medications may play a supporting role in specific cases but do not replace a gradual, individualized reduction schedule guided by an experienced physician.